PSA Screening Shows Sustained Prostate Cancer Mortality Reduction in 23-Year Study
Research demonstrates 13% relative reduction in prostate cancer deaths but highlights overdiagnosis concerns, prompting calls for risk-based screening approaches.
Research demonstrates 13% relative reduction in prostate cancer deaths but highlights overdiagnosis concerns, prompting calls for risk-based screening approaches.
A new study demonstrates the capability of a blood test in detecting ovarian cancer up to three years prior to diagnosis in prospectively collected samples.Â
UCLA Health researchers find cell-free DNA combined with machine learning can distinguish ALS from other neurological conditions.
A study of nearly 1,800 patients shows a threefold difference in sentinel node metastasis rates between high-risk and low-risk groups.
Deep-learning model trained on 4,000 samples shows 98.6% agreement with manual review while identifying additional organisms missed by technologists.
Researchers urge clinicians to integrate lipid management into prenatal care to mitigate elevated obstetric complications and cardiovascular risks.
From rising demand for comprehensive IgE profiles to the emergence of molecular allergen diagnostics, laboratories are central to how clinicians prepare for and manage September’s asthma spike.
Study of more than 13,000 individuals demonstrates improved precision for emergency department triage and patient outcomes.
Two biomarker panels demonstrated 91% sensitivity and specificity in symptomatic patients, potentially reducing the need for PET imaging confirmation.
The automated system uses ion exchange HPLC technology to deliver A1c results while detecting common hemoglobin variants.
The agreement aims to improve early detection and management of chronic kidney disease in underserved populations through integrated diagnostics and digital health solutions.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
TriVerity system demonstrated high sensitivity and specificity across more than 1,200 patients in pivotal SEPSIS-SHIELD trial.